Sun Pharmaceuticals Industries (NSE:SUNPHARMA) LT-Debt-to-Total-Asset : 0.00 (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is Sun Pharmaceuticals Industries LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Sun Pharmaceuticals Industries's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.00.

Sun Pharmaceuticals Industries's long-term debt to total assets ratio stayed the same from Dec. 2022 (0.00) to Dec. 2023 (0.00).

Sun Pharmaceuticals Industries LT-Debt-to-Total-Asset Historical Data

The historical data trend for Sun Pharmaceuticals Industries's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sun Pharmaceuticals Industries LT-Debt-to-Total-Asset Chart

Sun Pharmaceuticals Industries Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.02

0.03

0.01

Sun Pharmaceuticals Industries Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	0.01	-	-	-

Sun Pharmaceuticals Industries LT-Debt-to-Total-Asset Calculation

Sun Pharmaceuticals Industries's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2023 is calculated as

LT Debt to Total Assets (A: Mar. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Mar. 2023 )	/	Total Assets (A: Mar. 2023 )
	=	5637	/	807435.9
	=	0.01

Sun Pharmaceuticals Industries's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	0	/	0
	=

Sun Pharmaceuticals Industries (NSE:SUNPHARMA) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Sun Pharmaceuticals Industries LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Sun Pharmaceuticals Industries's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Sun Pharmaceuticals Industries (NSE:SUNPHARMA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sun Pharmaceuticals Industries Ltd (NSE:SUNPHARMA) » Definitions » LT-Debt-to-Total-Asset

Traded in Other Exchanges

524715:India

Address

Western Express Highway, Sun House, Plot No. 201 B/1, Goregaon (East), Mumbai, MH, IND, 400 063

Website

https://www.sunpharma.com

Sun Pharmaceuticals Industries Ltd is India's largest generic pharmaceutical manufacturer and the fourth largest in the world. The company's largest markets are the U.S. and India to make up the majority of revenue. The remaining is spread across both emerging and developed markets. In addition to generics, the company also produces and distributes name-brand formulas to specific geographies. It maintains manufacturing and research and development facilities globally to serve its markets but is primarily based in India.

Sun Pharmaceuticals Industries (NSE:SUNPHARMA) Headlines

No Headlines